KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Common Equity (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Common Equity readings, the most recent being -$119.2 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 74.96% to -$119.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$119.2 million, a 74.96% increase, with the full-year FY2025 number at -$119.2 million, up 74.96% from a year prior.
  • Common Equity hit -$119.2 million in Q4 2025 for Biocryst Pharmaceuticals, up from -$387.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$75.0 million in Q1 2021 to a low of -$476.2 million in Q1 2024.
  • Median Common Equity over the past 5 years was -$358.1 million (2023), compared with a mean of -$310.5 million.
  • Biggest five-year swings in Common Equity: crashed 2155.59% in 2021 and later skyrocketed 74.96% in 2025.
  • Biocryst Pharmaceuticals' Common Equity stood at -$107.0 million in 2021, then plummeted by 175.36% to -$294.6 million in 2022, then tumbled by 54.63% to -$455.5 million in 2023, then fell by 4.48% to -$475.9 million in 2024, then skyrocketed by 74.96% to -$119.2 million in 2025.
  • The last three reported values for Common Equity were -$119.2 million (Q4 2025), -$387.9 million (Q3 2025), and -$421.6 million (Q2 2025) per Business Quant data.